Topical application of sphingosine 1-phosphate receptor 1 prolongs corneal graft survival in mice

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3800-3807

  Zhu, Jing ^a   Liu, Yong ^b   Huang, Yifei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

Allogeneic corneal; Corneal disease; Sphingosine 1 phosphate receptor 1; Transplantation

Indexed keywords

AGENTS ACTING ON THE EYE; CANCER GROWTH FACTOR; CYCLOSPORIN A; EYE DROPS; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG; CYTOKINE;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CERVICAL LYMPH NODE; CONTROLLED STUDY; CORNEA OPACITY; CORNEA TRANSPLANTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; ANIMAL; CORNEA; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TOPICAL DRUG ADMINISTRATION;

MUS;

ADMINISTRATION, TOPICAL; ANIMALS; CORNEA; CORNEAL TRANSPLANTATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT SURVIVAL; IMMUNOPHENOTYPING; MALE; MICE; RECEPTORS, LYSOSPHINGOLIPID; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84922287242     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3230     Document Type: Article

References (43)

1. Oliva MS, Schottman T and Gulati M: Turning the tide of corneal blindness. Indian J Ophthalmo l60: 423-427, 2012.
2. Streilein JW: New thoughts on the immunology of corneal transplantation. Eye 17: 943-948, 2003.
3. Williams KA, Lowe M, Bartlett C, Kelly TL and Coster DJ: Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 86: 1720-1724, 2008.
4. Maguire MG, Stark WJ, Gottsch JD, et al: Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 101: 1536-1547, 1994.
5. Panda A, Vanathi M, Kumar A, Dash Y and Priya S: Corneal graft rejection. Surv Ophthalmol 52: 375-396, 2007.
6. Niederkorn JY: Immune mechanisms of corneal allograft rejection. Curr Eye Res 32: 1005-1016, 2007.
7. Chauhan SK, Saban DR, Lee HK and Dana R: Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol 182: 148-153 2009.
8. Cunnusamy K, Paunicka K, Reyes N, et al: Two different regulatory T cell populations that promote corneal allograft survival. Invest Ophthalmol Vis Sci 51: 6566-6574, 2010.
9. Inoue K, Kimura C, Amano S, et al: Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol 45: 378-382, 2001.
10. Shimazaki J, Den S, Omoto M, et al: Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 152: 33-39, 2011.
11. Zhang ZY, Zhang Z, Zug C, et al: AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 216: 59-65, 2009.
12. Hanessian S, Charron G, Billich A and Guerini D: Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg Med Chem Lett 17: 491-494, 2007.
13. Brinkmann V, Davis MD, Heise CE, et al: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457, 2002.
14. Pan S, Mi Y, Pally C, et al: A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 13: 1227-1234, 2006.
15. Sedláková K, Muckersie E, Robertson M, Filipec M and Forrester JV: FTY720 in corneal concordant xenotransplantation. Transplantation 79: 297-303, 2005.
16. Mayer K, Birnbaum F, Reinhard T, et al: FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88: 915-919, 2004.
17. Zhang EP, Müller A, Ignatius R and Hoffmann F: Significant prolongation of orthotopic corneal-graft survival in FTY720-treated mice. Transplantation 76: 1511-1513, 2003.
18. Cohen JA, Barkhof F, Comi G, et al: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415, 2010.
19. Zhang EP, Schrunder S and Hoffmann F: Orthotopic corneal transplantation in the mouse: a new surgical technique with minimal endothelial cell loss. Graefes Arch Clin Exp Ophthalmol 234: 714-719, 1996.
20. Brinkmann V, Cyster JG and Hla T: FYT720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4: 1019-1025, 2004.
21. Zhang JL, Sun DJ, Hou CM, et al: CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney. Transpl Immunol 24: 17-25, 2010.
22. Xie Y, Sun HX and Li D: Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccine 27: 757-764, 2009.
23. Küchle M, Cursiefen C, Nguyen NX, et al: Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 240: 580-584, 2002.
24. Xie L, Shi W, Wang Z, Bei J and Wang S: Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea 20: 748-752, 2001.
25. Bourges JL, Lallemand F, Agla E, et al: Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol Vis 12: 1461-1466, 2006.
26. Sinha R, Jhanji V, Verma K, et al: Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol 248: 1167-1172, 2010.
27. Ziaei M and Manzouri B: Topical cyclosporine in corneal transplantation. Cornea 29: Oct 29, 2014 (Epub ahead of print).
28. Unal M and Yucel I\; Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol 92: 1411-1414, 2008.
29. Poon A, Constantinou M, Lamoureux E and Taylor HR: Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol 36: 415-421, 2008.
30. Alalwani H, Omer Saleh B, Rocher N, et al: Advantages and limits of multiple grafts (third keratoplasty) under local cyclosporin 2%. J Fr Ophtalmol 33: 710-714, 2010 (In French).
31. Wang GY, Yang Y, Li H, et al: Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4(+) CD25(+) Foxp3(+) regulatory T cell expansion. Hepatol Res 42: 192-202, 2012.
32. Lu L, Ma J, Wang X, et al: Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur J Immunol 40: 142-152, 2010.
33. Hofmann U, Hu K, Walter F, et al: Pharmacological pre-and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol 160: 1243-1251, 2010.
34. Stanojlovic S, Schlickeiser S, Appelt C, et al: Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol 248: 1447-1456, 2010.
35. Matsuoka K, Kim HT, McDonough S, et al: Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 120: 1479-1493, 2010.
36. Schneider MA, Meingassner JG, Lipp M, Moore HD and Rot A: CCR7 is required for the in vivo function of CD4+CD25+ regulatory T cells. J Exp Med 204: 735-745, 2007.
37. Commodaro AG, Peron JP, Lopes CT, et al: Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci 51: 2568-74, 2010.
38. Sehrawat S and Rouse BT: Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators. J Immunol 180: 7636-7647, 2008.
39. Bocian K, Borysowski J, Wierzbicki P, et al: Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Nephrol Dial Transplant 25: 710-717, 2010.
40. Zeiser R, Nguyen VH, Beilhack A, et al: Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108: 390-399, 2006.
41. Yamagami S, Dana MR and Tsuru T: Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 21: 405-409, 2002.
42. Kobayashi T, Momoi Y and Iwasaki T: Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells. J Vet Med Sci 69: 887-892, 2007.
43. Li J, Ballim D, Rodríguez M, et al: The anti-proliferative function of the TGF-β1 signalling pathwayinvolves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem: Nov 4, 2014 (Epub ahead of print).